JP2008518969A - アルツハイマー病を治療するためのβ−セクレターゼ阻害薬として有用な２−アミノピリジン化合物 - Google Patents

アルツハイマー病を治療するためのβ−セクレターゼ阻害薬として有用な２−アミノピリジン化合物 Download PDF

Info

Publication number
JP2008518969A
JP2008518969A JP2007539354A JP2007539354A JP2008518969A JP 2008518969 A JP2008518969 A JP 2008518969A JP 2007539354 A JP2007539354 A JP 2007539354A JP 2007539354 A JP2007539354 A JP 2007539354A JP 2008518969 A JP2008518969 A JP 2008518969A
Authority
JP
Japan
Prior art keywords
group
alkyl
halogen
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007539354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518969A5 (enExample
Inventor
コバーン，クレイグ・エイ
ホロウエイ，エム・キヤサリン
ステイチエル，シヨーン・ジエイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2008518969A publication Critical patent/JP2008518969A/ja
Publication of JP2008518969A5 publication Critical patent/JP2008518969A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2007539354A 2004-10-29 2005-10-25 アルツハイマー病を治療するためのβ−セクレターゼ阻害薬として有用な２−アミノピリジン化合物 Pending JP2008518969A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62344104P 2004-10-29 2004-10-29
PCT/US2005/039932 WO2006060109A1 (en) 2004-10-29 2005-10-25 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2008518969A true JP2008518969A (ja) 2008-06-05
JP2008518969A5 JP2008518969A5 (enExample) 2008-10-30

Family

ID=36565355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539354A Pending JP2008518969A (ja) 2004-10-29 2005-10-25 アルツハイマー病を治療するためのβ−セクレターゼ阻害薬として有用な２−アミノピリジン化合物

Country Status (7)

Country Link
US (1) US7932275B2 (enExample)
EP (1) EP1807396B1 (enExample)
JP (1) JP2008518969A (enExample)
CN (1) CN101052618A (enExample)
AU (1) AU2005310239A1 (enExample)
CA (1) CA2585279A1 (enExample)
WO (1) WO2006060109A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111465603A (zh) * 2017-12-19 2020-07-28 勃林格殷格翰国际有限公司 作为γ-分泌酶调节剂的三唑并吡啶

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1940406A4 (en) * 2005-10-21 2009-11-18 Merck & Co Inc POTASSIUM CHANNEL INHIBITORS
EP2402317B1 (en) 2006-03-31 2013-07-03 Novartis AG DGAT inhibitor
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
CA2714058A1 (en) 2008-02-28 2009-09-03 Ivory D. Hills 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
ES2481823T3 (es) 2010-03-10 2014-07-31 Probiodrug Ag Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
JP2014524472A (ja) 2011-08-22 2014-09-22 メルク・シャープ・アンド・ドーム・コーポレーション Ｂａｃｅ阻害剤としての２−スピロ置換イミノチアジンならびにそのモノオキシドおよびジオキシド、組成物、ならびにそれらの使用
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN111533684B (zh) * 2020-05-29 2021-10-29 四川大学 一种吡啶化合物烯基化的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273820A (ja) * 1990-11-02 1992-09-30 Elan Corp Plc 調合物及び神経系疾患の治療に於けるその使用
WO2004080376A2 (en) * 2003-03-14 2004-09-23 Glaxo Group Limited Hydroxyethylamine compounds having asp2 inhibitory activity for the treatment of alzheimer’s disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001136A (es) * 2000-08-11 2003-06-24 Eisai Co Ltd Compuesto de 2-aminopiridina y uso medico del mismo.
US6951946B2 (en) * 2002-03-19 2005-10-04 Lexicon Pharmaceuticals, Inc. Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates
WO2003106405A1 (en) 2002-06-01 2003-12-24 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
CA2529739A1 (en) 2003-06-16 2005-01-20 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US20080287399A1 (en) 2004-12-14 2008-11-20 Astrazeneca Ab Substituted Aminopyridines and Uses Thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273820A (ja) * 1990-11-02 1992-09-30 Elan Corp Plc 調合物及び神経系疾患の治療に於けるその使用
WO2004080376A2 (en) * 2003-03-14 2004-09-23 Glaxo Group Limited Hydroxyethylamine compounds having asp2 inhibitory activity for the treatment of alzheimer’s disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111465603A (zh) * 2017-12-19 2020-07-28 勃林格殷格翰国际有限公司 作为γ-分泌酶调节剂的三唑并吡啶
CN111465603B (zh) * 2017-12-19 2024-01-09 勃林格殷格翰国际有限公司 作为γ-分泌酶调节剂的三唑并吡啶

Also Published As

Publication number Publication date
US7932275B2 (en) 2011-04-26
WO2006060109A1 (en) 2006-06-08
EP1807396A1 (en) 2007-07-18
CN101052618A (zh) 2007-10-10
AU2005310239A1 (en) 2006-06-08
EP1807396A4 (en) 2009-09-09
US20080161363A1 (en) 2008-07-03
EP1807396B1 (en) 2013-06-26
WO2006060109B1 (en) 2006-08-10
CA2585279A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
JP2008518969A (ja) アルツハイマー病を治療するためのβ−セクレターゼ阻害薬として有用な２−アミノピリジン化合物
JP7097373B2 (ja) キナーゼ阻害剤としてのアミノトリアゾロピリジン
JP5102397B2 (ja) アリールメチルベンゾキナゾリノンｍ１レセプターポジティブアロステリックモジュレーター
JP7095106B2 (ja) オキサジアゾール一過性受容器電位チャネル阻害剤
JP6476205B2 (ja) ＲＯＲγ修飾因子としてのヘテロ環式スルホン
JP7511294B2 (ja) Ｆｇｆｒ阻害剤化合物及びその使用
JP2008515989A (ja) アルツハイマー病を治療するためのβ−セクレターゼ阻害薬として有用なスピロピペリジン化合物
KR102240158B1 (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
JP2008526999A (ja) アルツハイマー病治療用ベータ−セクレターゼインヒビターとして活性な置換へテロ環含有三級カルビナミン
NO313293B1 (no) Substituerte pyrido- eller pyrimido-holdige 6,6- eller 6,7- bicykliske derivater, anvendelse derav og farmasöytisk preparat
JP2010523725A (ja) 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン
KR20140071384A (ko) C-kit 키나제 억제제로서의 화합물 및 조성물
KR20140105433A (ko) Pdgfr 키나제 억제제로서의 화합물 및 조성물
JP2008502684A (ja) アルツハイマー病を治療するためのベータ−セクレターゼ阻害剤として有用なピロリジン−３−イル化合物
KR20160098500A (ko) 플루오로-나프틸 유도체
WO2019244002A1 (en) Pyridinyl pyrazoles as modulators of roryt
KR20120101551A (ko) Ｍｇｌｕｒ５ 수용체의 알로스테릭 조절자로서 바이사이클릭 티아졸
JP6554547B2 (ja) Ｂａｃｅ１阻害剤
EP3526218A1 (en) Heterocyclic sulfones as ror gamma modulators
TW202024020A (zh) 治療神經退化性疾病之方法
JP6811187B2 (ja) インドロン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
TW202342453A (zh) Glp-1r調節化合物
US7816378B2 (en) Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
JP6787320B2 (ja) テトラヒドロオキセピノピリジン化合物
EP2516446B1 (en) Substituted hexahydrochromeno[3,4-b]pyrroles with affinity for the serotonin receptor (5-ht) family

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110531

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111108